Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Nature Communications|November 3, 2025
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22Elisia Villemure, Tom Januario, Mingshuo Zeng, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Nature Biotechnology|December 9, 2014
A comprehensive transcriptional portrait of human cancer cell linesChristiaan Klijn, Steffen Durinck, Eric W Stawiski, et al.
Nature Genetics|September 4, 2012
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerCharles M Rudin, Steffen Durinck, Eric W Stawiski, et al.
Journal of Medicinal Chemistry|May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft ModelsSummer A Baker Dockrey, Pravin Chandra, Huifen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Pageof 6